Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...

Pliant Therapeutics, Inc. announced the discontinuation of the BEACON-IPF Phase 2b trial assessing bexotegrast for patients with idiopathic pulmonary fibrosis due to safety concerns raised by an ...